May 13 – 17, 2019 | VIENNA – GRAZ – KLOSTERNEUBURG – KREMS

#### LIST OF PARTICIPANTS



James E. AUDIA, Ph.D. CBC Executive Director

**Chicago Biomedical Consortium (CBC)** Northwestern University 2205 Tech Drive, Hogan 2-100 Evanston, IL 60208

jeaudia1@northwestern.edu | T +1 847 467 6745 | C +1 312 270 3790

www.chicagobiomedicalconsortium.org

https://www.chicagobiomedicalconsortium.org/about/staff\_directory/

The mission of the Chicago Biomedical Consortium (CBC) is to stimulate collaboration among scientists at Northwestern University, The University of Chicago, the University of Illinois at Chicago and others to accelerate discovery that will transform biomedical research and improve human health. The CBC supports fundamental basic science with transformational potential and early translational research to de-risk academic discoveries and advance them toward clinical and commercial realization. CBC is funded by the Searle Funds at the Chicago Community Trust and has supported faculty recruitment, investments in infrastructure available broadly across the 3 institutions, and innovative biomedical research. Our educational efforts have helped to increase the pool of entrepreneurial faculty and students/graduates available to drive innovation in the community.





May 13 – 17, 2019 | VIENNA – GRAZ – KLOSTERNEUBURG – KREMS

## Marshallplan-Jubiläumsstiftung Austrian Marshall Plan Foundation Fostering Transatlantic Excellence



#### LIST OF PARTICIPANTS



**Dr. Vladimir BEZROOKOVE** Senior Research Associate

**California Pacific Medical Center Research Institute** 475 Brannan St #220 San Francisco, CA 94107

BezrooV@cpmcri.org | T +1 415 600 1763 | C +1 925 577 3048 https://www.sutterhealth.org/research

California Pacific Medical Center (CPMC) is the largest medical center of the Northern California, part of Sutter Health. It is a general/academic medical center and specialty hospital operating at multiple locations in San Francisco. It hosts also CPMC Research Institute which conducts basic science and clinical studies into a range of topics. CPMC's Center for Melanoma Research and Treatment is home of the nations most prestigious innovators in melanoma therapy and research.

May 13 – 17, 2019 | VIENNA – GRAZ – KLOSTERNEUBURG – KREMS

## Marshallplan-Jubiläumsstiftung Austrian Marshall Plan Foundation Fostering Transatlantic Excellence



#### LIST OF PARTICIPANTS



**Dr. Giovanni GADDA** Distinguished University Professor and Associate Chair of Chemistry

**Georgia State University** Department of Chemistry P.O. Box 3965 Atlanta, Georgia 30302-3965

ggadda@gsu.edu | T +1 404 413 5537 | C +1 404 428 2857

https://chemistry.gsu.edu/profile/ggadda/

*Georgia State University (GSU) has seven campuses throughout metro Atlanta and more than 51,000 students, of which 3,000+ are international; it has 10 colleges and schools and offers 250+ degree programs in 100 fields of study at the main Atlanta campus. GSU has been ranked the #2 most innovative, the #2 best undergraduate, and #10 most ethnically diverse university in the U.S. by U.S. News & World Report (2019).* 

The research interest of my group is in the general area of the mechanistic enzymology of redox enzymes, with a specific interest in flavin-dependent enzymes. The long-term objectives are to understand how enzymes can influence the energetics of reaction intermediates and transition states. These aspects are being studied by steady state kinetics and rapid reaction techniques using pH, viscosity and kinetic isotope effects, as well as mutagenesis, X-ray crystallography and computational approaches.

May 13 - 17, 2019 | VIENNA - GRAZ - KLOSTERNEUBURG - KREMS

### LIST OF PARTICIPANTS







Maureen HERRMANN Program and Administrative Director

HARVARD STEM CELL INSTITUTE Harvard University, Bauer Building, Room G02A 7 Divinity Avenue, Cambridge, MA 02138 USA T +1 617 496 6647 | mobile +1 339 222 8153 maureen\_herrmann@harvard.edu www.hsci.harvard.edu

https://hscrb.harvard.edu/people/maureen-herrmann

Harvard Stem Cell Institute researchers at Massachusetts General Hospital (MGH) succeeded in using reprogrammed human stem cells to make working blood vessels in mice that can survive for as long as nine months. The blood vessels were created with induced pluripotent stem cells (iPSCs) derived from the mature skin cells of both healthy adults and individuals with type 1 diabetes.

May 13 – 17, 2019 | VIENNA – GRAZ – KLOSTERNEUBURG – KREMS

### LIST OF PARTICIPANTS







**Andrew KOFF, PhD** Professor of Molecular Biology; Lab Head, The Andrew Koff Lab Professor, Sloan Kettering Institute;

Director and Chair of the Allied Programs in Biochemistry, Cell and Molecular Biology, Weill Cornell College of Medicine; Founder, Atropos Therapeutics; Head, laboratory of Cell Cycle Regulation, Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center RRL 917C, 1275 York Avenue New York, NY USA 10065

koffa@mskcc.org, a-koff@ski.mskcc.org | T +1 212 639 2354 | C +1 646 255 0057 https://www.mskcc.org/research/ski/labs/andrew-koff

*MSKCC, the world's oldest freestanding cancer center, is affiliated with Cornell University Medical College and Rockefeller University. MSKCC has 13 clinical departments, 17 disease management teams and 8 research departments in the Sloan Kettering Institute, which constitute almost 300 faculty, 300 post-docs, and 250 clinical fellows. The work in my laboratory straddles the transition from basic science, whether it was regulating the G1 commitment decision or as of now at how cells maintain themselves in quiescence and choose to enter senescence, into the clinical realm of the hospital, asking how these transitions affect the growth and development of tissues and disease.* 

Atropos Therapeutics is a very early stage start up identifying drugs that can modulate senescence, for applications in aging (senosuppressors).

*My laboratory has combined biochemical, molecular, cellular, and genetic approaches to investigate the roles of CDK inhibitors in differentiation, development, and cancer biology. An additional major focus of the laboratory is directed towards understanding how these gene products are regulated to accomplish these roles.* 

May 13 – 17, 2019 | VIENNA – GRAZ – KLOSTERNEUBURG – KREMS

# Marshallplan-Jubiläumsstiftung Austrian Marshall Plan Foundation Fostering Transatlantic Excellence



#### LIST OF PARTICIPANTS



**Bruce PALFEY, Ph.D.** Associate Professor, Biological Chemistry

**The University of Michigan** Department of Biological Chemistry 1150 W. Medical Center Dr., Ann Arbor, MI 48109-0606

brupalfdumich.edu | T +1 734 615 2452 | C +1 734 904 9979

https://medicine.umich.edu/dept/biochem/bruce-palfey-phd

The University of Michigan is one of the leading public research universities in the United States. The research of the faculty of the Department of Biological Chemistry is concerned with macromolecular chemistry, structure, and interactions. The department offers Ph.D. and M.S. degrees, and contributes to a variety of other graduate and undergraduate degrees administered by other units on campus.

*My research focuses on uncovering in atomic detail how protein molecules called enzymes are able to speed specific reactions many orders of magnitude. This research requires the use of specialized technology to observe chemistry on the millisecond time-scale and develop strategies that can characterize fleeting molecular configurations. The deep knowledge produced by such studies can be used to design new pharmeceuticals or engineer enzymes to produce valuable chemicals.* 

May 13 – 17, 2019 | VIENNA – GRAZ – KLOSTERNEUBURG – KREMS

## Marshallplan-Jubiläumsstiftung Austrian Marshall Plan Foundation Fostering Transatlantic Excellence



#### LIST OF PARTICIPANTS



Claudia SCHMIDT-DANNERT Distinguished McKnight Professor

**University of Minnesota** College of Biological Sciences Dept. Biochemistry, Molecular Biology & Biophysics & BioTechnology Institute

1479 Gortner Avenue 140 Gortner Laboratory St. Paul, MN 55108, USA

schmi232@umn.edu | T 612-625-5782 | C +1 651 247 9684, +49 176 5292 2910 https://cbs.umn.edu/schmidt-dannert-lab/home

The University of Minnesota (UM) has the sixth largest campus in the US and ranks eights in research spending among public US university with an \$8.6 billion annual economic impact. The UM is one of two universities in the US that consists of colleges and schools that span the full breadth of academic and professional disciplines ranging. Its medical & professional school, science and engineering and agricultural colleges are major hubs of innovation and entrepreneurship. More than 20 fortune 500 companies are headquartered in Minnesota (e.g. Cargill, 3M, Ecolab, General Mills, St. Jude Medical, United Health) or have a large presence in Minnesota (e.g. Boston Scientific, Beckman Coulter).

We are currently pursuing two major research focus areas: In one focus area, we are exploring and harnessing the unique biosynthetic and redox catalytic machineries of higher fungi. We are screening and characterizing the unique portfolios of bioactive compounds (natural products) made by mushrooms by building a field-to-lab biobank and identifying their biosynthetic pathways and oxidative enzymes. Another focus in our lab is the design of genetically programmable and self-assembling protein-based nanoarchitectures for applications in biocatalysis, biosynthesis, and for the fabrication of new types of self-assembling bio-nanomaterials for a variety of applications.

May 13 – 17, 2019 | VIENNA – GRAZ – KLOSTERNEUBURG – KREMS

#### LIST OF PARTICIPANTS



Sandra VIDAK, Ph.D. Postdoctoral Fellow

National Cancer Institute, NIH Center for Cancer Research 9000 Rockville Pike Bethesda, MD, 20892

sandra.vidak@nih.gov | T +1 240 760-6737 | C +1 301 547-1660 https://www.linkedin.com/in/sandra-vidak-phd-76b44912

The Center for Cancer Research is the largest division of the NCI intramural research program and comprises nearly 250 basic and clinical research groups working on a wide spectrum of biological and biomedical problems ranging from visualizing and understanding the structure of individual genes and proteins, developing novel methods for drug discovery, to inventing biomedical devices and technology and creating innovative ways to treat patients in the NIH Clinical Center.



May 13 – 17, 2019 | VIENNA – GRAZ – KLOSTERNEUBURG – KREMS

#### LIST OF PARTICIPANTS

#### Accompanied by:



**Peter Sedlmayer** Austrian Trade Commissioner

ADVANTAGE AUSTRIA - Austrian Trade Commission Chicago 500 N Michigan Avenue, Suite 1950, Chicago, IL 60611 T +1 312 644 5556 ext 201 | C +1 312 493 7152 chicago@advantageaustria.org | www.advantageaustria.org/us



Markus Schweiger Executive Director

**Austrian Marshall Plan Foundation** Walcherstraße 11A, 1020 Vienna, Austria

m.schweiger@marshallplan.at | T +43 1 50175 – 419 | C +43 650 555 66 50 www.marshallplan.at



**Matthias Grabner** Project Manager Health, Medical Technology, Life Science, Pharma

ADVANTAGE AUSTRIA Austrian Federal Economic Chamber Wiedner Hauptstraße 63, 1045 Vienna/Austria

T +43 5 90900 4209 | matthias.grabner@wko.at C +43 664 817 97 41 | www.advantageaustria.org





Wiedner Hauptstraße 63, 1045 Vienna/Austria

T +43 5 90900 4346 | C +43 664 817 98 49

Claudia Moser

Marshallplan-Jubiläumsstiftung

Austrian Marshall Plan Foundation

claudia.moser@wko.at | www.advantageaustria.org

